Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) and Cabaletta Bio (NASDAQ:CABA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.
Volatility & Risk
Outlook Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 2.58, indicating that its share price is 158% more volatile than the S&P 500.
Insider & Institutional Ownership
11.2% of Outlook Therapeutics shares are owned by institutional investors. 4.8% of Outlook Therapeutics shares are owned by company insiders. Comparatively, 9.9% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Outlook Therapeutics | 0 | 1 | 4 | 0 | 2.80 |
| Cabaletta Bio | 0 | 1 | 6 | 1 | 3.00 |
Outlook Therapeutics presently has a consensus price target of $10.20, indicating a potential upside of 628.57%. Cabaletta Bio has a consensus price target of $22.71, indicating a potential upside of 1,268.33%. Given Cabaletta Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Cabaletta Bio is more favorable than Outlook Therapeutics.
Valuation & Earnings
This table compares Outlook Therapeutics and Cabaletta Bio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Outlook Therapeutics | N/A | N/A | -$75.37 million | ($7.42) | -0.19 |
| Cabaletta Bio | N/A | N/A | -$67.68 million | ($2.15) | -0.77 |
Cabaletta Bio is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Outlook Therapeutics and Cabaletta Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Outlook Therapeutics | N/A | N/A | -225.12% |
| Cabaletta Bio | N/A | -50.10% | -45.49% |
Summary
Cabaletta Bio beats Outlook Therapeutics on 9 of the 12 factors compared between the two stocks.
About Outlook Therapeutics
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
About Cabaletta Bio
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
